Engflag

Levacetam

Quick links to important sections

Levacetam

Levacetam_RO

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levacetam

Property Description
Active Ingredient Levetiracetam (alpha-ethyl-2-oxo-1-pyrrolidineacetamide)
Form Tablets, oral solution, intravenous (IV) solution
Pharmacological Class Second-generation Antiepileptic Drug (AED)
Common Use Foundational control of seizure disorders
Origin Synthetic compound (Pyrrolidone derivative)

What Type of Medicine is Levacetam and What is its Core Purpose?

Levacetam is a synthetic pharmaceutical preparation containing the active chemical substance Levetiracetam, which is classified as a second-generation Antiepileptic Drug (AED), also known as an anticonvulsant. Levetiracetam belongs to the pyrrolidine antiepileptic class, identifying its unique chemical structure among antiepileptic agents. This classification indicates that the medicine is utilized for its effect on stabilizing nerve activity in the brain, a mechanism that has been clinically recognized for its therapeutic efficacy in managing complex conditions.

The core purpose of this single-ingredient medication is to provide necessary central nervous system stabilization. Levetiracetam is structurally unrelated to existing AEDs, representing a distinct advancement in seizure management. This distinction shows it offers a novel approach to controlling the sudden, excessive neuronal electrical discharges that define epilepsy and associated seizure disorders, such as managing partial-onset seizures.

Composition and Available Pharmaceutical Forms

The sole active ingredient is Levetiracetam, which exists clinically as the pharmacologically active S-enantiomer. The drug is manufactured as a single-ingredient product in multiple dosage forms to accommodate various administration requirements. These preparations include immediate-release and extended-release tablets for sustained oral (per os) use. Furthermore, it is available as a liquid oral solution and a sterile intravenous (IV) solution for parenteral administration. The availability of both oral and intravenous preparations ensures flexibility, allowing for consistent systemic delivery of Levetiracetam during both routine and acute care scenarios, a benefit highly valued in clinical settings.

Regulatory References

  1. EMA Public Assessment Report for Keppra
  2. EMA Assessment Report

What side effects are possible with Levacetam?

Possible side effects and safety information

The official safety profile of Levacetam is structured around adverse reactions classified by frequency and system-organ class, as documented by government regulatory authorities.

Frequency and System-Organ Classifications

Adverse reactions are grouped according to how often they appear in clinical data. Very Common (ge 1/10) effects include nasopharyngitis, somnolence, and headache. Common (ge 1/100 to < 1/10) effects encompass Nervous System Disorders (such as dizziness, fatigue, and tremor) and Psychiatric Disorders (including aggression, irritability, depression, and anxiety), alongside common gastrointestinal complaints.

Serious Adverse Reactions and Safety Considerations

The label specifies rare but clinically significant adverse reactions. These include a documented risk of Suicidal Ideation and Behavior and rare, severe cutaneous adverse reactions, such as Steven-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Other rare effects involve the hematologic system (e.g., pancytopenia) and organ systems (e.g., hepatic failure and acute kidney injury).

Safety notes for specific groups are included, explicitly stating that clearance is reduced in patients with renal impairment, requiring consideration. Additionally, certain behavioral adverse reactions may be observed more frequently in pediatric patients than in adults.

Time-related safety patterns note that somnolence and dizziness are often reported more frequently at the beginning of treatment or following dose increases, with a tendency to resolve over time. Regulatory documents emphasize close observation for psychiatric and behavioral changes, which are required safety monitoring.

Overdose and Emergency Response

A Levacetam overdose is primarily defined by documented effects on the central nervous system. Officially reported clinical manifestations have included specific neurological and behavioral changes such as somnolence, drowsiness, agitation, and aggression, frequently associated with a depressed level of consciousness. Overdose can progress to severe outcomes, including life-threatening respiratory depression and coma, according to regulatory documents.

In the event of a suspected overdose, the official guidance mandates contacting a Certified Poison Control Center for the most current management information. Urgent medical evaluation is necessary when severe CNS effects or difficulty breathing are apparent.

Management relies on supportive measures, as no specific antidote is known. Regulatory prescribing information indicates that treatment should consist of general supportive care, including necessary precautions to maintain the airway, and continuous monitoring of vital signs and clinical status. Elimination of unabsorbed medicine may be attempted via procedures such as gastric lavage or emesis when clinically appropriate. Furthermore, hemodialysis should be considered for treatment, as it effectively clears a significant portion of Levacetam from the body. Accidental overdose cases have been reported in children, particularly those aged 6 months to 11 years.

Therapeutic Uses of Levacetam

What Levacetam Treats: Main Uses and Benefits

Levacetam is an antiepileptic drug (AED) that is commonly used to provide supportive therapeutic relief for symptoms of increased neurological or muscular activity associated with epilepsy and seizure disorders. Its therapeutic application spans several critical areas of seizure management.

Controlling Symptomatic Manifestations

The medication is commonly used to help manage symptoms in conditions involving episodic or fluctuating manifestations, including focal (partial-onset) seizures, Primary Generalized Tonic-Clonic Seizures (PGTCS), and Myoclonic Seizures relevant in generalized syndromes like Juvenile Myoclonic Epilepsy. The core therapeutic benefit is that it helps address symptom clusters related to seizure-related manifestations, which may assist with managing symptoms that interfere with daily comfort. It is applied when appropriate as both monotherapy or adjunctive therapy in adults and children.

“It is commonly used to help with symptoms that create noticeable functional strain, providing assistance in maintaining daily stability.”

In addition to initial management, Levacetam is also applied in clinical settings that involve acute or unstable symptom patterns, such as where seizures are persistent or uncontrolled by initial treatment. This offers additional symptomatic support for managing symptoms that interfere with daily functioning, which may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

Quick Fact: Relief for Seizure-Related Manifestations

Regulatory References

  1. FDA DailyMed label for Levetiracetam

Eligibility and Restrictions for Use

Eligibility and Official Restrictions

Regulatory agencies define specific population groups that are either approved to use Levacetam, prohibited from using it, or require special, conditional consideration.

Contraindications: Who Must Not Use Levacetam?

The medicine is absolutely contraindicated for use in any patient with a known hypersensitivity (allergy) to the active substance Levetiracetam, to other pyrrolidone derivatives, or to any of the specific excipients contained within the formulation [Source: FDA Labeling; EMA SmPC].

Age-Specific Eligibility

Population Group Eligibility Status (as per labeling)
Monotherapy Approved for adolescents and adults from 16 years of age. Use is not established below this age threshold.
Adjunctive Therapy Approved for adults and children from 4 years of age for most indications, and in infants from 1 month of age for specific formulations and seizure types.

Conditional Use Populations

Use of Levacetam is restricted and requires consideration of the patient's physiological status, as the medicine is eliminated primarily by the kidneys:

  • Impaired Renal Function: Patients with any degree of compromised kidney function are eligible only under conditional circumstances. Official labeling mandates that an individual's renal function must be assessed and monitored before and during use.
  • Severe Hepatic Impairment: Dose adjustments are generally not required unless the condition is compounded by significant renal impairment.
  • Older Adults: Eligibility is generally maintained, but close monitoring and assessment of renal function are recommended due to the higher prevalence of age-related changes in kidney clearance.

Pregnancy and Lactation Status

Official labeling for use in pregnant and breastfeeding women classifies eligibility as conditional. The drug is known to cross the placenta and is excreted into human milk. Therefore, use is not routinely recommended unless the potential benefit is determined to outweigh the potential risk, as documented in regulatory risk summaries.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Levacetam (Levetiracetam) is characterized by a low potential for metabolic drug-drug interactions, as regulatory documents confirm it is not significantly metabolized by, nor does it typically inhibit or induce, major liver Cytochrome P450 (CYP) enzymes. There are no medicinal products formally classified as contraindicated for co-administration in the official regulatory labeling.

Documented interactions primarily involve two classes of effect:

Pharmacodynamic and Substance Interactions

Co-administration with other Central Nervous System (CNS) depressants may result in an additive pharmacodynamic effect, potentially increasing somnolence or fatigue. Official documentation also notes that alcohol consumption may enhance these central nervous system effects.

Pharmacokinetic and Administration Interactions

Interacting Substance/Condition Documented Interaction Outcome
Enzyme-Inducing AEDs (e.g., Carbamazepine) Officially documented to increase the apparent clearance of Levetiracetam by approximately 22%.
Methotrexate Co-administration may lead to higher blood levels of Methotrexate; regulatory guidance recommends careful monitoring.
Probenecid Inhibits the renal tubular secretion of the major, inactive metabolite (ucb L057), but does not alter the clearance of Levetiracetam itself.
Food Decreases the peak plasma concentration (Cmax) by approximately 20% and delays the time to peak concentration (Tmax), but the overall extent of absorption (AUC) is not affected.
Renal Impairment The clearance of Levetiracetam is reduced in this population, which is an important pharmacokinetic consideration documented in the label.

Mechanism of Action

The mechanism of action of Levacetam involves the specific modulation of a protein engaged in regulating chemical signaling between nerve cells in the brain.

Targeting the Synaptic Vesicle Glycoprotein 2A (SV2A)

The drug acts as a neuromodulator by binding with high affinity to SV2A, an essential protein located on the synaptic vesicles that store and release neurotransmitters. This targeted molecular interaction interferes with the proper release machinery within the nerve endings. This action is mechanistically separate from agents that primarily modulate ion channels or enhance GABAergic neurotransmission.

Selective Reduction of Excitatory Neurotransmitter Release

The molecular binding event limits the Ca^2+-dependent release of excitatory neurotransmitters, such as glutamate, from the presynaptic terminal. This functional consequence is most pronounced during pathological, high-frequency electrical activity, contributing to the dampening of signals associated with high-frequency neural communication and amplification.

Inhibiting Neuronal Hypersynchronization

Intervention in the release of excitatory signals leads to the modulation of neuronal network function and restriction of high-frequency electrical propagation within the central nervous system. The overall physiological effect is the inhibition of neuronal hypersynchronization, a process that contributes to the modulation of electrical activity.

Dosage and Administration Information

How Levacetam is Used

Levacetam (Levetiracetam) is administered according to a structured protocol, ensuring consistent delivery of the medicine. Its use is guided by the route of administration, the required dosing schedule, and specific administration conditions.

The medicine is administered through two primary routes: oral for routine, long-term maintenance, and intravenous (IV) for temporary substitution when the oral route is not feasible.

Administration and Dosing Schedule

Administration Parameter Official Guideline
Standard Initial Adult Dose 500 mg twice daily (total 1000 mg/day)
Frequency Pattern Immediate-release forms and IV solution are administered twice daily; extended-release forms are taken once daily
Titration Schedule The dose is gradually adjusted in increments of up to 1000 mg/day every two weeks to reach the maintenance range
Timing Relative to Food May be taken with or without food

Procedural and Population-Specific Conditions

Accurate delivery is critical, with specific instructions governing preparation and intake. Oral tablets, particularly the extended-release form, must be swallowed whole to ensure proper delivery. If the IV formulation is used, the concentrate must be diluted in at least 100 mL of compatible fluid and infused over a period of 15 minutes. Dosing adjustments are required for certain populations, such as older adults and patients with renal impairment, where the dose is reduced based on calculated creatinine clearance. If a dose is missed, patients are generally instructed to take it as soon as remembered, unless it is close to the time of the next dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Levacetam

The official research record for Levacetam (Levetiracetam) is built upon several types of clinical evaluations, primarily randomized controlled trials (RCTs), which represent a significant level of clinical data. These studies, reviewed by governmental health authorities, describe the evidence base for which the medicine has been evaluated in conditions characterized by fluctuating or episodic manifestations. Research contributes to understanding symptom patterns in the observed populations.

Evidence for Use in Partial-Onset Seizures

Clinical evaluation for partial-onset seizures (focal seizures) relies on multiple short-term, double-blind, placebo-controlled RCTs. These trials primarily evaluated the medicine as an adjunctive therapy (an addition to existing medication) in both adults and a wide range of pediatric patients. The key outcomes measured were the change in the frequency of partial-onset seizures from a baseline period and the responder rate. Findings describe patterns observed in the studies, suggesting a change in seizure frequency counts was measured during the short-term evaluation periods compared to placebo.

Evidence for Use in Generalized Seizure Syndromes

The evidence base for generalized seizure syndromes was explored in controlled trials. For Primary Generalized Tonic-Clonic Seizures (PGTCS), research evaluated the medicine as adjunctive therapy in adults and adolescents, focusing on the change in the frequency of PGTCS. For Myoclonic Seizures, studies reported findings related to the change in Myoclonic Seizure Days per week. Data for certain groups, particularly for Myoclonic and PGTCS in very young children (under 12 years of age), are still emerging.

Long-Term Research and Uncertainty

The controlled efficacy trials had relatively limited follow-up durations, typically under four months. Understanding long-term outcomes and the persistence of effects is therefore based on other study designs, such as open-label studies that monitored responses over extended periods. Comparative evidence is lacking regarding the medicine's use as the sole initial therapy (monotherapy) against all established alternatives. Research describes patterns related to the rate of medicine elimination from the body in patients with kidney impairment.

Frequently Asked Questions (FAQ)

Common questions about Levacetam (FAQ)

Q: How is Levacetam thought to be different from other similar treatments?

Official prescribing information indicates that Levacetam is classified as a pyrrolidine antiepileptic medicine. This classification shows it is structurally and mechanistically distinct from many of the older antiepileptic drugs (AEDs). This distinction shows a unique approach to modulating electrical activity in the brain.

Q: How long do side effects from Levacetam typically last?

Studies show that common side effects, such as somnolence (drowsiness) and dizziness, are often reported more frequently at the beginning of treatment or after a dose change. Official documentation notes that these effects tend to lessen as the body adjusts to the medicine over time.

Q: Is Levacetam generally intended for short-term or long-term use?

Regulatory information indicates that treatment for conditions like epilepsy is typically a long-term strategy. Levacetam is generally used for ongoing maintenance to help control seizures. Regulatory warnings state that this medication should not be stopped suddenly.

Q: When is the best time of day to take Levacetam?

The goal of administration is consistency. For forms that are taken twice daily, the official guidance recommends spacing the doses evenly throughout the day. Extended-release forms are designed to be taken once daily, and taking the medicine around the same time each day helps maintain stable levels in the body.

Q: Does taking Levacetam require special monitoring or routine blood tests?

Yes, official guidelines indicate that monitoring is necessary in certain populations. Due to how the drug is eliminated, regulatory documents indicate that the patient's renal function (kidney health) should be assessed and monitored. Additionally, close observation for psychiatric, behavioral, and rare hematologic (blood cell) changes is required during treatment.

Q: What are the key differences between brand-name Levacetam and its generic forms?

The Food and Drug Administration (FDA) requires that both the brand-name and generic forms contain the exact same active ingredient (levetiracetam) and be proven bioequivalent. The key differences usually relate to the manufacturing, such as the inactive ingredients (fillers or dyes), and the cost of the product.

Q: Is Levacetam considered a controlled substance?

No, official regulatory bodies classify Levacetam as a prescription-only (Rx-only) medicine. It is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration (DEA), meaning it is not associated with abuse potential.

Q: Does Levacetam treat a condition or only help manage the symptoms?

Official information from health authorities states that Levacetam helps to control seizures and manage the underlying condition. It is intended for maintenance therapy, but it does not cure the underlying disease.

Q: Is Levacetam a type of antidepressant?

No. Official labeling confirms that Levacetam is chemically classified as a Second-generation Antiepileptic Drug (AED), also known as an anticonvulsant. Its mechanism of action is distinct from that of medicines used to treat depression.

Q: Can taking Levacetam lead to weight gain or weight loss?

Official regulatory documents state that changes in weight (gain or loss) were observed during clinical trials. Changes in weight were not listed among the most common adverse reactions, suggesting that weight changes are not a frequent effect.

Q: Can Levacetam be taken with over-the-counter pain relievers like ibuprofen?

The official drug interaction section does not list a specific pharmacokinetic interaction with common over-the-counter pain relievers such as ibuprofen. Official guidance typically recommends that a healthcare professional review all co-administered medications.

Q: Is it safe to use herbal products while on Levacetam?

Official guidance from health authorities indicates that healthcare providers are typically informed about all prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products a patient is taking. This is necessary because complete interaction data is often lacking for herbal supplements.

Q: How quickly does Levacetam start to show an effect after beginning treatment?

Pharmacokinetic studies indicate that after taking an oral dose, the drug is rapidly absorbed and typically reaches its peak concentration in the blood within about one hour. A stable level of the drug, known as steady-state, is usually achieved after two days of twice-daily dosing.

Q: Is there a process for stopping Levacetam treatment?

Yes. The FDA label includes a warning that Levacetam is to be withdrawn gradually under medical supervision. This process is necessary to minimize the potential risk of increased seizure frequency, including status epilepticus.

Q: Is Levacetam considered a new or recently developed medication?

Levacetam (Levetiracetam) is classified as a second-generation Antiepileptic Drug (AED). It was first approved by the FDA in 1999. This places it within the category of second-generation AEDs.

Q: Is it true that Levacetam can be habit-forming?

Regulatory bodies have not listed Levacetam as a controlled substance, and it is not associated with abuse or dependence potential. However, official warnings indicate that abrupt discontinuation can lead to a risk of increased seizure frequency.

Q: Does Levacetam have any potential to show up on standard drug screening tests?

Official information confirms that the drug is not chemically related to the substances typically screened for in common workplace or standard drug panels. Specialized laboratory tests are available, but these are typically used to measure the drug’s level in the blood.

Q: Where can a person find the official prescribing information for Levacetam?

The complete and official prescribing information, including the Medication Guide, is available on government health websites. These resources include the Food and Drug Administration (FDA) and DailyMed, which provide detailed regulatory documents.

How should Levacetam be stored and disposed of?

Storage and Disposal Requirements

Storage and disposal of Levacetam (Levetiracetam) must comply with conditions detailed in official regulatory labeling to ensure stability and safety.

Storage Conditions

Oral tablets and solution are required to be stored at Controlled Room Temperature, typically 15^circmathrmC to 30^circmathrmC (59^circmathrmF to 86^circmathrmF). The oral solution must carry the instruction Do not freeze. The intravenous (IV) solution concentrate must be protected from light until use. All formulations are required to be stored out of the sight and reach of children.

Stability and Handling

Once the IV solution is diluted, it has a limited stability period and must be used or discarded within the specified time, typically four hours at room temperature. The medication should be kept in its original container.

Disposal

Unused or expired Levacetam must be disposed of in accordance with local pharmaceutical waste regulations. Medicines should not be disposed of via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levacetam found in:

A-Z Index: